CollPlant explores strategic options as revenue drops following milestone loss
CollPlant Biotechnologies (NASDAQ:CLGN) initiated a formal review of its strategic alternatives after a sharp contraction in milestone revenue caused its first-quarter sales to drop to near-zero, forcing the company to slash its workforce by half.

_1410320_640x360_2501785155949-640x360.webp&w=3840&q=75)








_1410298_640x360_2501779523868-640x360.webp&w=3840&q=75)
